SEHK:6990
SEHK:6990Biotechs

Does Breakthrough Status For Sacituzumab Tirumotecan-Keytruda Combo Reshape Kelun-Biotech’s Oncology Strategy (SEHK:6990)?

Sichuan Kelun-Biotech Biopharmaceutical recently announced that its TROP2-directed ADC sacituzumab tirumotecan, combined with MSD’s KEYTRUDA, received Breakthrough Therapy Designation in China for first-line treatment of certain advanced non-small cell lung cancer patients, while its CEO highlighted pipeline progress and globalisation plans at the J.P. Morgan Healthcare Conference. The clustering of multiple Breakthrough Therapy Designations around sacituzumab tirumotecan, alongside...
SEHK:1783
SEHK:1783Construction

Will Envision Greenwise’s New Board Lineup Strengthen Its Governance Story For Investors (SEHK:1783)?

Envision Greenwise Holdings has appointed veteran finance executive Fei Yiping as a non-executive director from 16 January 2026, while also confirming its full board and committee structure to align with Hong Kong listing requirements. Fei’s long tenure in senior finance roles at major Chinese and international businesses adds heavyweight accounting and governance expertise to Envision Greenwise’s boardroom. Next, we’ll examine how Fei Yiping’s appointment and broader board reshaping may...